Baxter International INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NYSE
Baxter International Inc. posted a net loss of $957 million in 2025, driven by significant impairment charges and product recalls, despite operational sales growth.
NYSE
10-K: Baxter International Inc. Reports Fiscal Year 2024 Results, Completes Kidney Care Business Sale
Baxter International Inc.'s 2024 10-K filing reveals a year of strategic shifts, including the sale of the Kidney Care business and a new operating model, alongside financial results impacted by Hurricane Helene and global economic conditions.
NYSE
Baxter International Inc.'s 2023 10-K filing details a year of strategic changes, including a planned Kidney Care business spinoff, a new operating model, and the sale of its BioPharma Solutions business, alongside a review of its financial performance.